A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray

[1]  E. Petricoin,et al.  A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  E. Petricoin,et al.  Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. , 2009, Clinical colorectal cancer.

[3]  E. Petricoin,et al.  Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.

[4]  E. Petricoin,et al.  Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine , 2015, PROTEOMICS - Clinical Applications.

[5]  L. Liotta,et al.  Reverse-phase protein microarrays: application to biomarker discovery and translational medicine , 2007, Expert review of molecular diagnostics.

[6]  M. Papotti,et al.  Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis. , 2014, The new microbiologica.

[7]  D. V. Von Hoff,et al.  Tumor-stromal interactions in pancreatic cancer. , 2013, Critical reviews in oncogenesis.

[8]  P. Hammerman,et al.  Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Griffith,et al.  Markers of Field Cancerization: Proposed Clinical Applications in Prostate Biopsies , 2012, Prostate cancer.

[10]  Xiao-Fan Wang,et al.  Signaling cross-talk between TGF-β/BMP and other pathways , 2009, Cell Research.

[11]  Emanuel F Petricoin,et al.  Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.

[12]  E. Petricoin,et al.  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.

[13]  H. Tanke,et al.  Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[14]  M. Salto‐Tellez,et al.  Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. , 2013, European urology.

[15]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[16]  H. Martinez-Rodriguez,et al.  Understanding the colon cancer stem cells and perspectives on treatment , 2015, Cancer Cell International.

[17]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[18]  B F Warren,et al.  The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  V. Poli,et al.  STAT3 can serve as a hit in the process of malignant transformation of primary cells , 2012, Cell Death and Differentiation.

[21]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[22]  E. Petricoin,et al.  Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis , 2014, Leukemia.

[23]  A. Strongin,et al.  Timp‐2 binding with cellular MT1‐MMP stimulates invasion‐promoting MEK/ERK signaling in cancer cells , 2009, International journal of cancer.

[24]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[25]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[26]  E. Petricoin,et al.  Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. , 2014, Cancer research.

[27]  E. Petricoin,et al.  Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors , 2015, Oncotarget.

[28]  P. Humphrey,et al.  Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.

[29]  Tomasz Arodz,et al.  Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures , 2013, Molecular Cancer Research.

[30]  Jianmei Wei,et al.  A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker , 2008, Molecular Cancer Therapeutics.

[31]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[32]  E. Petricoin,et al.  Tissue is alive: New technologies are needed to address the problems of protein biomarker pre‐analytical variability , 2009, Proteomics. Clinical applications.

[33]  Y. DeClerck,et al.  Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. , 2013, Cancer research.

[34]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[35]  E. Petricoin,et al.  A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[36]  Joseph M. Negri,et al.  The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.

[37]  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations , 2013, Clinical & Experimental Metastasis.

[38]  A. Chan,et al.  AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. , 2013, Experimental cell research.

[39]  E. Petricoin,et al.  A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process* , 2008, Molecular & Cellular Proteomics.

[40]  Michele Signore,et al.  Antibody Validation by Western Blotting. , 2017, Methods in molecular biology.

[41]  E. Petricoin,et al.  Application of molecular technologies for phosphoproteomic analysis of clinical samples , 2014, Oncogene.

[42]  H. Kung,et al.  Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK , 2004, Oncogene.

[43]  E. Winer,et al.  Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Liotta,et al.  Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. , 2011, Methods in molecular biology.

[45]  G. Dakubo,et al.  Clinical implications and utility of field cancerization , 2007, Cancer Cell International.

[46]  Yasuo Watanabe,et al.  Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. , 2006, Oncology reports.

[47]  D. Louis,et al.  Deregulation of a STAT3–Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness , 2008, The Journal of Neuroscience.

[48]  E. Petricoin,et al.  Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL , 2010, PloS one.

[49]  S. Wang.  The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy , 2011, Journal of signal transduction.

[50]  M. Moore,et al.  Genomic Rearrangements of PTEN in Prostate Cancer , 2013, Front. Oncol..

[51]  A. Bardelli,et al.  Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia , 2011, Proceedings of the National Academy of Sciences.